Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | PRNP | P04156 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214901 | 0.94 | STING1 (0.53) | STING1RXFP1PRNPTSHRMAPK1 | |
| SCHEMBL1609773 | 0.89 | STING1 (0.65) | STING1RXFP1PRNPTSHRMAPK1 | |
| SCHEMBL5229127 | 0.88 | MCL1 (0.57) | STING1RXFP1PRNPTSHRMAPK1 | |
| SCHEMBL5226644 | 0.87 | STING1 (0.52) | STING1RXFP1PRNPTSHRMAPK1 | |
| SCHEMBL6025520 | 0.84 | STING1 (0.52) | STING1RXFP1PRNPTSHRMAPK1 | |
| SCHEMBL6021129 | 0.82 | STING1 (0.48) | STING1RXFP1PRNPTSHRMAPK1 | |
| SCHEMBL5226003 | 0.82 | MCL1 (0.57) | STING1RXFP1PRNPTSHRMAPK1 | |
| SCHEMBL1254412 | 0.80 | MCL1 (0.51) | STING1RXFP1PRNPTSHRMAPK1 | |
| SCHEMBL6468939 | 0.79 | STING1 (0.48) | STING1RXFP1PRNPTSHRMAPK1 | |
| SCHEMBL6020655 | 0.79 | STING1 (0.48) | STING1RXFP1PRNPTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636212-B1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO¬B|THIOPHENES AS THERAPEUTIC AGENTS | WARNER LAMBERT CO (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1636212-A1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1636211-A1 | 3-ARYLSULFANYL AND 3-HETEROARYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1636210-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | CONNOLLY MICHAEL KEVIN (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2004108716-A1 | 3-ARYLSULFANYL AND 3-HETEROARYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108714-A1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108713-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248954-A1 | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents | GOGLIOTTI ROCCO DEAN (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040248953-A1 | 3-Arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents | GOGLIOTTI ROCCO DEAN (US) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248954-A1 | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents | MALT1, BPNT1, CYP1B1 | STING1 2995/4885RXFP1 1623/4885PRNP 4235/4885 |
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | MALT1, CYP1B1, WEE2 | STING1 2586/4885RXFP1 2023/4885PRNP 4385/4885 |
| US-20040248953-A1 | 3-Arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents | SULT2A1, SULT1A1, SULT1E1 | STING1 3144/4885RXFP1 966/4885PRNP 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.